Julie Strizki, PhD

Principal Scientist
Merck & Co., Inc.
West Point, Pennsylvania, United States

Julie Strizki, PhD, is a Principal Scientist in Infectious Disease and Vaccines at Merck and Co. She currently serves as a Clinical Virolgist, supporting several early and late stage antiviral programs including, molnupiravir; letermovir, raltegravir, and the MK-1654 RSV surveillance program. Prior to her current position, she focused her research work on early drug discovery of novel agents to treat HIV and other viruses.

.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 1473 - Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro

  Friday, October 21, 2022
  12:20 PM – 12:25 PM US ET